EV Push vs Reality: Why Indians Are Choosing Hybrids Instead

SUMMARY

In this episode, we decode three key trends: India’s auto shift where EV sales rose 76% but hybrids grew faster at 83% despite policy support via the FAME Scheme; a proposed 126% tariff by the U.S. Department of Commerce that could hit Indian solar exports; and the weight-loss drug opportunity as semaglutide’s patent expiry opens the market for Sun Pharma, Zydus Lifesciences, Dr. Reddy's Laboratories, and Natco Pharma to challenge Novo Nordisk and Eli Lilly and Company.